JP2022534202A5 - - Google Patents

Info

Publication number
JP2022534202A5
JP2022534202A5 JP2021568858A JP2021568858A JP2022534202A5 JP 2022534202 A5 JP2022534202 A5 JP 2022534202A5 JP 2021568858 A JP2021568858 A JP 2021568858A JP 2021568858 A JP2021568858 A JP 2021568858A JP 2022534202 A5 JP2022534202 A5 JP 2022534202A5
Authority
JP
Japan
Prior art keywords
vector
treatment
rtt
neurons
rtt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021568858A
Other languages
English (en)
Japanese (ja)
Other versions
JP7624410B2 (ja
JP2022534202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064092 external-priority patent/WO2020234363A2/en
Publication of JP2022534202A publication Critical patent/JP2022534202A/ja
Publication of JP2022534202A5 publication Critical patent/JP2022534202A5/ja
Application granted granted Critical
Publication of JP7624410B2 publication Critical patent/JP7624410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021568858A 2019-05-21 2020-05-20 レット症候群の治療におけるコレステロール 24-ヒドロラーゼのための発現ベクター Active JP7624410B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19175767.3 2019-05-21
EP19175767 2019-05-21
PCT/EP2020/064092 WO2020234363A2 (en) 2019-05-21 2020-05-20 Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome

Publications (3)

Publication Number Publication Date
JP2022534202A JP2022534202A (ja) 2022-07-28
JP2022534202A5 true JP2022534202A5 (cg-RX-API-DMAC7.html) 2023-05-31
JP7624410B2 JP7624410B2 (ja) 2025-01-30

Family

ID=66751865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568858A Active JP7624410B2 (ja) 2019-05-21 2020-05-20 レット症候群の治療におけるコレステロール 24-ヒドロラーゼのための発現ベクター

Country Status (5)

Country Link
US (1) US20220233654A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972631B1 (cg-RX-API-DMAC7.html)
JP (1) JP7624410B2 (cg-RX-API-DMAC7.html)
CN (1) CN114555813A (cg-RX-API-DMAC7.html)
WO (1) WO2020234363A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205303A1 (en) * 2022-04-20 2023-10-26 The Regents Of The University Of California Microglial cells as therapeutic targets in neurodevelopmental disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2554380C (en) * 2004-02-17 2015-05-19 The Hospital For Sick Children Mecp2e1 gene
ES2582200T3 (es) * 2007-09-12 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilización de vectores víricos portadores del gen CYP46A1 para el tratamiento de la enfermedad de Alzheimer
ES2566495T3 (es) * 2010-10-15 2016-04-13 Inserm - Institut National De La Santé Et De La Recherche Médicale Vector de expresión para colesterol 24-hidrolasa en terapia de la enfermedad de Huntington
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
RU2017110868A (ru) * 2014-09-25 2018-10-25 Колд Спринг Харбор Лаборатори Лечение синдрома ретта
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
FI3574091T3 (fi) * 2017-01-30 2023-05-03 Brainvectis Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
EP3635122A4 (en) * 2017-06-06 2021-03-31 University of Massachusetts SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME

Similar Documents

Publication Publication Date Title
JP2022068181A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2018148927A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2020533959A5 (cg-RX-API-DMAC7.html)
JP2023534999A5 (cg-RX-API-DMAC7.html)
JP2021106619A5 (cg-RX-API-DMAC7.html)
JP2022551986A5 (cg-RX-API-DMAC7.html)
JP2022508182A5 (cg-RX-API-DMAC7.html)
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP2009526067A5 (cg-RX-API-DMAC7.html)
JP2021523702A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2022531809A5 (cg-RX-API-DMAC7.html)
JP2016503405A5 (cg-RX-API-DMAC7.html)
JP2020519284A5 (cg-RX-API-DMAC7.html)
JP2023534037A5 (cg-RX-API-DMAC7.html)
JP2021522173A5 (cg-RX-API-DMAC7.html)
JP2024543001A5 (cg-RX-API-DMAC7.html)
JP2023537980A5 (cg-RX-API-DMAC7.html)
JP2023515692A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)
JP2023524414A5 (cg-RX-API-DMAC7.html)
JP2023551873A5 (cg-RX-API-DMAC7.html)
JP2021525245A5 (cg-RX-API-DMAC7.html)